LTR Pharma has announced the publication of a third-party validation of its nasal-delivery erectile dysfunction (ED) treatment Spontan (PD 21 May), strengthening LTR's regulatory dossier as it progresses the drug towards commercialisation.
The above article was sent to subscribers in Pharmacy Daily's issue from 20 Aug 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Aug 25